

May 23, 2023

Notice Regarding Recalculated 340B Ceiling Prices and Offers of Refunds to 340B Covered Entities

SK Life Science, Inc. (SKLSI) has recently completed a minor restatement of government pricing values. As a result of the recalculated 340B Ceiling Prices, SKLSI has determined that, pursuant to 42 U.S.C. §256b(d)(1)(B)(ii) and 42 C.F.R. § 10.11(b)(4), a refund is or may be owed to 340B Covered Entities that purchased any of the below NDCs during the period of July 1, 2021, through June 30, 2022

SKLSI has asked the Office of Pharmacy Affairs ("OPA") to post this notice on OPA's public website to ensure transparency. SKLSI has identified all Covered Entities that may be owed a refund for purchases during this timeframe and is in the process of directly contacting any Covered Entity owed a refund greater than \$50.00 by U.S. mail.

SKLSI is also committed to issuing a refund to any Covered Entity that was overcharged on a PHS purchase made between July 1, 2021 and June 30, 2022 that was not contacted directly via U.S. mail – this includes Covered Entities owed a refund of less than \$50.00.

Covered Entities that wish to inquire can do so by emailing SKLSI at <u>qzhang@sklsi.com</u> by June 30, 2024 with a subject line of "340B Refile" and your entities 340B ID. The Covered Entity will be asked to provide proper documentation of an overcharge during the relevant time period, such as the applicable NDC(s), purchase volume(s) and time period(s). However, SKLSI is committed to working with eligible covered entities to determine if there was over payment and issue the appropriate refund owed, if any.

Refund checks will be issued to the facility and matching Federal Tax ID number.

NDC	NDC Description	340B Sales
		Periods
71699-0050-30	XCOPRI 50 MG TABLET	Q3 2021 – Q2 2022
71699-0100-30	XCOPRI 100 MG TABLET	Q3 2021 – Q2 2022
71699-0103-56	XCOPRI 150MGx28 / 200MGX28 MAINTENANCE PACK	Q2 2022
71699-0150-30	XCOPRI 150 MG TABLET	Q4 2021 – Q2 2022
71699-0200-30	XCOPRI 200 MG TABLET	Q4 2021 – Q2 2022
71699-0201-28	XCOPRI 12.5MG X 14/25MG X 14 TITRATION PACK	Q3 2021
71699-0202-28	XCOPRI 50MG X 14/100MG X 14 TITRATION PACK,28	Q3 2021
71699-0203-28	XCOPRI 150MG X 14/200MG X 14 TITRATION PACK	Q3 2021